Anixa Biosciences to Present at the Sachs Associates 5th Annual Immuno-Oncology BD&L and Investment Forum

On May 21, 2019 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body’s immune system to fight cancer, reported that it will be presenting at the Sachs Associates 5th Annual Immuno-Oncology BD&L and Investment Forum to be held May 31, 2019 in Chicago (Press release, Anixa Biosciences, MAY 21, 2019, View Source [SID1234536498]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mike Catelani, COO and CFO of Anixa, will provide an overview of the company, its most recent accomplishments and upcoming milestones, with a focus on its chimeric endocrine receptor t-cell (CER-T) treatment for ovarian and other cancers. Management will also be available for one-on-one meetings with investors who are registered to attend the conference.

Details of Anixa’s presentation are as follows:

Event:

5th Annual Immuno-Oncology: BD&L and Investment Forum

Date:

Friday, May 31, 2019

Time:

12:10 p.m.

Location:

PR Track A – Room Sinclair Ballroom

Waldorf Astoria Chicago, Chicago, IL

The 5th Annual Immuno-Oncology BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment.